# Krystal Biotech (KRYS) — Analyst Forecast

KRYS · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/krys/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 12 | 1 | 0 | 13 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $361.00 | $397.60 | $441.00 | 5 |

Last price $330.00 (as of Oct 16, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 15, 2026 | HC Wainwright & Co. | Maintained | Buy | $361.00 |
| Sep 24, 2026 | Goldman Sachs | Maintained | Buy | $441.00 |
| Sep 21, 2026 | B of A Securities | Maintained | Buy | $400.00 |
| Aug 14, 2026 | RBC Capital | Initiated Coverage | Outperform | $400.00 |
| Aug 4, 2026 | Citigroup | Maintained | Buy | $386.00 |
| Jul 14, 2026 | B of A Securities | Maintained | Buy | $396.00 |
| Jun 18, 2026 | TD Cowen | Maintained | Buy | $403.00 |
| Jun 16, 2026 | HC Wainwright & Co. | Maintained | Buy | $361.00 |
| Jun 1, 2026 | HC Wainwright & Co. | Maintained | Buy | $310.00 |
| May 22, 2026 | HC Wainwright & Co. | Maintained | Buy | $310.00 |
| May 18, 2026 | HC Wainwright & Co. | Maintained | Buy | $310.00 |
| May 5, 2026 | Evercore ISI Group | Maintained | Outperform | $300.00 |
| May 5, 2026 | Citigroup | Maintained | Buy | $378.00 |
| May 4, 2026 | HC Wainwright & Co. | Maintained | Buy | $310.00 |
| Mar 27, 2026 | Wolfe Research | Initiated Coverage | Peer Perform | — |
| Feb 25, 2026 | Guggenheim | Maintained | Buy | $284.00 |
| Feb 18, 2026 | Chardan Capital | Maintained | Buy | $323.00 |
| Feb 18, 2026 | Citigroup | Maintained | Buy | $371.00 |
| Feb 17, 2026 | Jefferies | Maintained | Buy | $371.00 |
| Feb 2, 2026 | Goldman Sachs | Maintained | Buy | $327.00 |

## Frequently Asked Questions

### What is the price target for KRYS stock?

The average 12-month analyst price target for Krystal Biotech (KRYS) is $397.60, with a high estimate of $441.00 and a low of $361.00, across 5 analysts.

### Is KRYS a buy, sell, or hold?

Analysts covering Krystal Biotech currently average a Buy rating: 12 buy, 1 hold and 0 sell, from 13 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for KRYS?

The average price target of $397.60 implies 20.48% upside from the last price of $330.00.

### What is the latest analyst rating on KRYS?

On Oct 15, 2026, HC Wainwright & Co. maintained Krystal Biotech at Buy with a price target of $361.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).